SCALOP

ISRCTN96169987 📎

Regimen

Experimental
Capecitabine 830 mg/m2 BID + 50.4 Gy / 28 fx radiation.
Control
Gemcitabine 300 mg/m2 weekly + 50.4 Gy / 28 fx radiation.

Population

Histologically proven locally advanced PDAC, tumor ≤6 cm, WHO PS 0-1, 28 UK centers. All patients received 12 weeks induction GemCap, then randomized if stable/responding.

Key finding

SCALOP showed capecitabine-based chemoradiation improves OS over gemcitabine-based chemoradiation after induction GemCap in locally advanced PDAC. Established capecitabine (not gemcitabine) as the preferred radiosensitizer in LA-PDAC when chemoRT is used.

Source: PMID 23474363

Timeline

    Guideline citations

    • NCCN PANCREATIC (p.65)